⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Familial Chylomicronemia Syndrome Global Market Analysis and Forecast, 2025-2035: Healthcare Access and Education Enhance FCS Market Expansion
globenewswire.com
IONS
ARWR
ABT
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
prnewswire.com
NTLA
ASTX
RZLT
IONS
KALV
BCRX
TAK
KAVL
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
globenewswire.com
BIIB
IONS
Biogen Completes Acquisition of Alcyone Therapeutics
globenewswire.com
BIIB
IONS
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
businesswire.com
IONS
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
businesswire.com
IONS
Ionis to present at upcoming investor conferences
businesswire.com
IONS
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
businesswire.com
IONS
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
businesswire.com
IONS
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
businesswire.com
IONS